Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case study follows Budi (alias), a patient from Indonesia who was diagnosed with an esophageal leiomyoma — a benign tumor of the esophagus — and traveled to a JCI-accredited hospital in China for specialized treatment. His tumor was actually discovered by accident, during an unrelated hernia surgery in Malaysia, which meant he suddenly needed a level of specialized care that wasn't part of his original treatment plan. For patients and families facing a similar unexpected diagnosis, ChinaCureLink offers a direct path to that same kind of specialized care — connecting patients with hospitals experienced in diagnosing and treating rare tumors like his, and coordinating every step from case review to treatment and follow-up.
Key Takeaways |
|
Patient Background
Budi H. (alias) is a patient from Semarang, Indonesia. In late 2024, he began experiencing troubling symptoms after meals — dark-colored vomiting after lying down to sleep, along with a recurring burning sensation in his chest. Seeking answers, he traveled to Malaysia in December 2024 for a medical check-up and consultation with a gastroenterologist, which led to a diagnosis of a hiatus hernia.
The Care Team and Approach
Budi underwent hernia surgery in Malaysia in March 2025. During that procedure, his surgical team discovered an additional growth located outside his esophageal tract — a finding that hadn't been part of the original diagnosis. Back home in Indonesia, a family member referred him to Professor Wen (pseudonym), who connected him with a JCI-accredited hospital in China recognized for its non-invasive surgical and interventional techniques.
Budi traveled to China in January 2026, where he was diagnosed with an esophageal leiomyoma. There, he was supported by Cindy (pseudonym), a staff member and translator at the hospital, along with a broader team of doctors, professors, and medical staff. Budi described the entire team as genuinely caring, and noted that language was never a barrier — the hospital had translators available in English, Indonesian, Thai, and several other languages.
Treatment Timeline/ Process
In Indonesia
Developed nighttime symptoms: dark-colored vomiting after meals and a burning chest sensation
In Malaysia
December 2024: Medical check-up and gastroenterology consultation; diagnosed with a hiatus hernia
March 2025: Underwent hernia surgery; an additional growth outside the esophageal tract was discovered during the procedure
In China
January 2026: Referred by a family connection to a JCI-accredited hospital in China
Diagnosed with an esophageal leiomyoma
Received care from a multidisciplinary team, supported by multilingual translation staff
Completed treatment and returned home to Indonesia to resume normal activities
Outcome
Budi completed his treatment in China and returned home to Semarang to resume his regular activities. Esophageal leiomyomas are benign, slow-growing tumors, and surgical removal is the standard, well-established treatment for symptomatic cases — this account reflects Budi's own description of a completed course of care, not an independently documented clinical outcome.
How ChinaCureLink Can Help Patients to Access This Treatment
Cases like Budi's often begin with a diagnosis that shifts midway through treatment — what starts as one condition can uncover a second, more specialized issue elsewhere. ChinaCureLink helps patients in this situation get a clear second opinion and connects them with JCI-accredited hospitals in China equipped to diagnose and treat rare or complex tumors, while coordinating medical record translation, specialist matching, travel logistics, and multilingual support from first inquiry through follow-up care.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
What should I do if a doctor finds an unexpected growth during another surgery?
An incidental finding like this typically calls for a specialist opinion and further diagnostic imaging before deciding on treatment. ChinaCureLink can help arrange a case review with a specialist in China to clarify next steps.
Is language a barrier when getting cancer or tumor treatment in China as an Indonesian patient?
ChinaCureLink provide translators in multiple languages, including Indonesian, so patients and families can communicate clearly with their care team throughout diagnosis and treatment.
How do I get a second opinion on a rare tumor diagnosis from overseas?
Patients typically start by sharing medical records, imaging, and pathology reports for a specialist to review. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in their specific condition.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
